Literature DB >> 21810164

Age-dependent intrathecal opioid escalation in chronic noncancer pain patients.

Salim M Hayek1, I Elias Veizi, Samer N Narouze, Nagy Mekhail.   

Abstract

BACKGROUND: Age and gender may exert important influences on opioid responsiveness and chronic pain. These effects have not been explored in the setting of chronic intrathecal (IT) opioid therapy. The objective of this study was to evaluate the effect of age and sex on IT opioid requirements during the first year after implantation of an intrathecal drug delivery system (IDDS) in chronic noncancer pain patients.
DESIGN: Retrospective study. METHODS AND PATIENT POPULATION: In this retrospective study, 135 chronic noncancer pain patients consecutively implanted with IDDSs for opioid therapy had their first year postimplant records examined.
RESULTS: Similar pain relief was achieved at 12 months after implant in both age groups. Relative to the dose at implant, younger patients had significantly higher rates of IT opioid dose escalation compared with older patients at 12 months (750 ± 450% in patients ≤50 years old vs 195 ± 120% in patients >50 years old, P < 0.001). Oral opioid consumption was significantly decreased at 12 months in the older patient population (140 ± 89 to 62 ± 35 mg/day at 12 months, P < 0.001, n = 85), while in the younger patient group, there was no change in oral opioid consumption (128 ± 81 mg/day to 105 ± 140 mg/day at 12 months, P = 0.65, n = 50). Gender-based analysis (55% males and 45% females) revealed similar reductions in pain scores during the first year postimplant. Oral opioid consumption was significantly higher in females (126 ± 138 mg) vs males (79 ± 89 mg) at 12 months postimplant; however, IT opioid dose escalation at 12 months postimplant was not statistically different between males and females.
CONCLUSION: IT opioid dose escalation occurs more steeply in the younger (under 50 years old) IDDS patient population without a concomitant significant decrease in oral consumption of opioids. Age-dependent changes may have important clinical implications on the effectiveness of IT opioid therapy in noncancer pain and its potential complications. Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810164     DOI: 10.1111/j.1526-4637.2011.01188.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  10 in total

Review 1.  Intrathecal Analgesia for Chronic Refractory Pain: Current and Future Prospects.

Authors:  Catherine Smyth; Nadera Ahmadzai; Jason Wentzell; Ashley Pardoe; Andrew Tse; Tiffany Nguyen; Yvette Goddard; Shona Nair; Patricia A Poulin; Becky Skidmore; Mohammed T Ansari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Intrathecal therapy for chronic pain: current trends and future needs.

Authors:  Salim M Hayek; Michael C Hanes
Journal:  Curr Pain Headache Rep       Date:  2014-01

Review 3.  Managing Chronic Non-Malignant Pain in the Elderly: Intrathecal Therapy.

Authors:  Barbara Kleinmann; Tilman Wolter
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

4.  Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients.

Authors:  Lucy Chen; Trang Vo; Lindsey Seefeld; Charlene Malarick; Mary Houghton; Shihab Ahmed; Yi Zhang; Abigail Cohen; Cynthia Retamozo; Kristen St Hilaire; Vivian Zhang; Jianren Mao
Journal:  J Pain       Date:  2013-02-26       Impact factor: 5.820

Review 5.  Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain.

Authors:  Michael Saulino; Philip S Kim; Erik Shaw
Journal:  J Pain Res       Date:  2014-11-10       Impact factor: 3.133

Review 6.  Intrathecal Therapy for Cancer-Related Pain.

Authors:  Brian M Bruel; Allen W Burton
Journal:  Pain Med       Date:  2016-04-28       Impact factor: 3.750

Review 7.  Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.

Authors:  Timothy R Deer; Jason E Pope; Michael C Hanes; Gladstone C McDowell
Journal:  Pain Med       Date:  2019-04-01       Impact factor: 3.750

8.  Intraoperative anti-inflammatory drugs combined with no drainage after MIS-TLIF in the treatment of recurrent lumbar disc herniation: an RCT.

Authors:  Jinpeng Du; Junsong Yang; Liang Yan; Lequn Shan; Wentao Wang; Yong Fan; Dingjun Hao; Dageng Huang
Journal:  J Orthop Surg Res       Date:  2021-01-07       Impact factor: 2.359

Review 9.  Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient.

Authors:  Jose De Andres; Salim Hayek; Christophe Perruchoud; Melinda M Lawrence; Miguel Angel Reina; Carmen De Andres-Serrano; Ruben Rubio-Haro; Mathew Hunt; Tony L Yaksh
Journal:  Front Pain Res (Lausanne)       Date:  2022-06-16

Review 10.  Intrathecal pain management: a team-based approach.

Authors:  Jeremy A Adler; Neona M Lotz
Journal:  J Pain Res       Date:  2017-11-03       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.